Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8. doi: 10.1007/s00259-008-0769-2. Epub 2008 Apr 17.

PMID:
18418596
2.

Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, Grassetto G, Rubello D, Nanni C, Franchi R.

Biomed Pharmacother. 2008 Dec;62(10):667-71. doi: 10.1016/j.biopha.2008.01.010. Epub 2008 Mar 3.

PMID:
18358680
3.

Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?

Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.

Clin Nucl Med. 2014 Jan;39(1):e27-34. doi: 10.1097/RLU.0b013e31827a216b.

PMID:
24217539
4.

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.

Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):765-70. doi: 10.1007/s00259-008-1030-8. Epub 2009 Jan 10.

PMID:
19137293
5.

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):67-77. doi: 10.1007/s00259-009-1205-y.

PMID:
19618183
6.

A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1800-8. doi: 10.1007/s00259-013-2548-y. Epub 2013 Sep 27.

PMID:
24072345
7.

Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.

Kagna O, Pirmisashvili N, Tshori S, Freedman N, Israel O, Krausz Y.

AJR Am J Roentgenol. 2014 Dec;203(6):1317-23. doi: 10.2214/AJR.14.12588.

PMID:
25415711
8.

Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.

Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):68-75.

9.

Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, Bal C.

Nucl Med Commun. 2012 Jul;33(7):766-74. doi: 10.1097/MNM.0b013e3283541157.

PMID:
22531829
10.

Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.

Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, Bal C.

AJR Am J Roentgenol. 2011 Nov;197(5):1221-8. doi: 10.2214/AJR.11.7298.

PMID:
22021518
11.

(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):722-7. doi: 10.1007/s00259-009-1349-9. Epub 2010 Jan 27.

PMID:
20107793
12.

The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.

Haidar M, Shamseddine A, Panagiotidis E, Jreige M, Mukherji D, Assi R, Abousaid R, Ibrahim T, Haddad MM, Vinjamuri S.

Nucl Med Commun. 2017 Feb;38(2):170-177. doi: 10.1097/MNM.0000000000000623.

PMID:
27922538
13.

The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin.

Kazmierczak PM, Rominger A, Wenter V, Spitzweg C, Auernhammer C, Angele MK, Rist C, Cyran CC.

Eur Radiol. 2017 Apr;27(4):1676-1684. doi: 10.1007/s00330-016-4475-3. Epub 2016 Jul 19.

PMID:
27436022
14.

Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?

Ambrosini V, Campana D, Nanni C, Cambioli S, Tomassetti P, Rubello D, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1278-83. doi: 10.1007/s00259-012-2146-4. Epub 2012 May 15.

PMID:
22584487
15.

Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.

Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1258-66. doi: 10.1007/s00259-016-3319-3. Epub 2016 Jan 28.

PMID:
26819103
16.

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, Mishani E, J Gross D.

Mol Imaging Biol. 2011 Jun;13(3):583-593. doi: 10.1007/s11307-010-0374-1.

PMID:
20652423
17.

18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.

Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, Masson S, Walter T, Houzard C, Scoazec JY, Hervieu V, Vuillez JP, Cornu C, Janier M, Borson-Chazot F.

Nucl Med Commun. 2011 Feb;32(2):91-7. doi: 10.1097/MNM.0b013e3283412143.

PMID:
21076344
18.

68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. doi: 10.1007/s00259-012-2309-3. Epub 2013 Jan 5.

PMID:
23291643
19.

68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, Montini GC, Mattioli S, Grassetto G, Al-Nahhas A, Franchi R, Fanti S.

Nucl Med Commun. 2009 Apr;30(4):281-6. doi: 10.1097/MNM.0b013e32832999c1.

PMID:
19247211
20.

Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns.

Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, Tshori S, Glaser B, Bocher M, Salmon A, Chisin R, Gross DJ, Freedman N.

Clin Nucl Med. 2012 Jan;37(1):57-62. doi: 10.1097/RLU.0b013e3182393404.

PMID:
22157030

Supplemental Content

Support Center